A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab

Project: Research

Status	Finished
Effective start/end date	10/5/15 → 10/4/18

Project Details